In a victory for pharmaceutical company Amneal, a Delaware court has invalidated claims of three patents covering Noven Pharmaceuticals’ Minivelle oestrogen product.
Amarin has announced it will seek an en banc rehearing of a decision at the US Court of Appeals for the Federal Circuit that failed to revive its patents on heart medicine Vascepa.
Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.
Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.
Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.
A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior.
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.
Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.